![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Lenvatinib_Structural_Formula_V1.svg/640px-Lenvatinib_Structural_Formula_V1.svg.png&w=640&q=50)
Lenvatinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lenvatinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.[4]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Lenvima, others |
Other names | E7080 |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 85% (estimated) |
Protein binding | 98–99% |
Metabolism | CYP3A4, aldehyde oxidase, non-enzymatic |
Metabolites | Desmethyl-lenvatinib (M2) and others |
Elimination half-life | 28 hours |
Excretion | ~65% feces, 25% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H19ClN4O4 |
Molar mass | 426.86 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Close